# Evaluating the Efficacy and Safety of Embella (Deoxycholic Acid, Produced by Espad Pharmed Co.) Injection in the Management of Superficial Lipomas

> **NCT07014163** · NA · RECRUITING · sponsor: **Espad Pharmed** · enrollment: 10 (estimated)

## Conditions studied

- Lipoma

## Interventions

- **DEVICE:** Embella (Deoxycholic acid, produced by Espad Pharmed Co.)

## Key facts

- **NCT ID:** NCT07014163
- **Lead sponsor:** Espad Pharmed
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-21
- **Primary completion:** 2026-03-20
- **Final completion:** 2026-06-20
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07014163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07014163, "Evaluating the Efficacy and Safety of Embella (Deoxycholic Acid, Produced by Espad Pharmed Co.) Injection in the Management of Superficial Lipomas". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07014163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*